Verastem reported Q3 2026 financial results and a business update, including commercial activity and progress in its VS-7375 clinical program. The company gave

Verastem reported Q3 2026 financial results and a business update, including commercial activity and progress in its VS-7375 clinical program. The company gave no added detail in the statement; a CEO transition to Michael P. Bailey is set for Jan. 1, 2027.